Clinical trial NCT01946295: Famotidine in Schizophrenia
Official title: Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Schizophrenia
Lead sponsor: University of Helsinki
Sponsor class: OTHER
Collaborators: name: Karolinska Institutet
name: Region Stockholm
name: City of Helsinki
name: Stanley Medical Research Institute
name: Ahokas foundation, Finland
First posted: 2013-09-19
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective of the trial is to study if famotidine add-on treatment is more effective than placebo add-on in reducing symptoms of schizophrenia among patients receiving insufficient response to ongoing antipsychotic treatment.


Eligibility criteria: Inclusion Criteria:

* ICD-10 diagnosis of schizophrenia (F20.00-20.39, F20.5, F20.9) who have had the disorder for at least 5 years and who are on disability pension. (This means that their treatment response is not satisfactory and for the purpose of this study, the subjects are potentially treatment resistant).
* Clinical Global Impression (CGI) severity score of at least 3.
* No changes in schizophrenia treatment within 12 weeks before study inclusion.
* Written informed consent
* The subjects must fulfil schizophrenia criteria both according to DSM- IV (295.10, .20, .30, .60, .90) (American Psychiatric association) and the Research Diagnostic Criteria for schizophrenia (RDC) \[40\]. They must also have at least mild residual symptoms (CGI 3 points). The DSM-IV diagnosis will be verified by use of the SCID-I \[41\]. The DSM-IV is clearly the most commonly used in psychiatric research, so this is important to be able to generalize the findings. However, several previous studies have used the RDC, so to be able to compare the results, we will diagnose the patients according to both systems.
* Women of child-bearing age will be included only of they use adequate contraception, or if we can otherwise verify that the subject is not pregnant (s-HCG), the possibility of pregnancy is negligible (e.g. the personnel of the housing facility reports that the person has not had sexual relationships for years) and the subject approves to remain sexually abstinent for the duration of the study.

Exclusion Criteria:

* Epilepsy or a history of unclear seizures, stroke, Parkinson's disease, AIDS
* History of substance addiction or abuse within 3 months prior to enrolment.
* Individuals who are deemed at risk for aggressive behaviour or suicide
* If their laboratory tests, EKG or other clinical observation warrants exclusion, they will be excluded
* Women who are pregnant or breast-feeding subjects will not be included in the study.
* Patients with any serious unstable physical illness will also be excluded
* Patients who have been deemed to be legally incapacitated according to Finnish or Swedish law.
* Regular Uuse of H2-antagonists as prescribed by a physician.
* Known allergy to famotidine or any other component of interventional drug will be excluded.
* Ongoing treatment with clozapine and dixyrazine.
* Clinical condition "very much improved" or "much improved", assessed by CGI, during the placebo lead-in
* Renal insufficiency (P-creatinine not within normal range. Glomerular filtration rate \<30 ml/min according to the Cockcroft-Gault formula. )
* Liver insufficiency (S-ALAT elevated more than 2-fold above the laboratory specific normal range)

Primary outcomes:
measure: Change from Baseline in Positive and Negative Syndrome Scale (PANSS) at 8 weeks
timeFrame: Rating at start of treatment (0 weeks) and at end of treatment (8 weeks)
Secondary outcomes:
measure: Change from Baseline in Clinical Global Impression (CGI) scale at 8 weeks
timeFrame: Rating at start of treatment (0 weeks) and at end of treatment (8 weeks)
measure: Change from Baseline in Calgary Depression Scale (CDS) at 8 weeks
timeFrame: Rating at start of treatment (0 weeks) and at end of treatment (8 weeks)
measure: Change from Baseline in The Overall Anxiety Severity and Impairment Scale (OASIS)at 8 weeks
timeFrame: Rating at start of treatment (0 weeks) and at end of treatment (8 weeks)
measure: Change from Baseline in CogState scores at 8 weeks
timeFrame: Rating at start of treatment (0 weeks) and at end of treatment (8 weeks)
measure: Change from baseline in nightly sleep duration measured with actigraphy at 8 weeks
timeFrame: Measurement at start of treatment (0 weeks) and at end of treatment (8 weeks)
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital Psychiatry Centre
city: Helsinki
country: Finland
facility: Helsinki University
city: Helsinki
country: Finland
facility: Social services and Healthcare, City of Helsinki
city: Hyvinkää
country: Finland
facility: Kellokoski Hospital
city: Stockholm
country: Sweden
facility: Karolinska Institutet
city: Stockholm
country: Sweden
facility: Norra Stockholms Psykiatri, Stockholm County Council
Study officials:
affiliation: University of Helsinki
name: Jesper Ekelund, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Meskanen K, Ekelund H, Laitinen J, Neuvonen PJ, Haukka J, Panula P, Ekelund J. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2013 Aug;33(4):472-8. doi: 10.1097/JCP.0b013e3182970490.